The Alliance for Regenerative Medicine: Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan
ATMPs are uniquely positioned to attack cancer at its source, bringing life-changing benefits to patients
BRUSSELS, BELGIUM - February 3, 2021
The Alliance for Regenerative Medicine (ARM) the global voice of the regenerative medicine and advanced therapies sector applauds the EU Beating Cancer Plan s identification of Advanced Therapy Medicinal Products (ATMPs) as part of a comprehensive cancer solution. ATMPs include cell and gene therapies that have already revolutionized the treatment of some aggressive forms of blood cancers and hold great promise for addressing other types of cancer.
Share this article
Share this article
NOIDA, India, Jan. 29, 2021 /PRNewswire/ A comprehensive overview of the gene therapy market is recently added by UnivDatos Market Insights to its humongous database. The gene therapy market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. This innovative report makes use of several analyses to get a closer outlook on the gene therapy market. The gene therapy market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the gene therapy market at the global and regional levels.
Global Chromatography Resin Market COVID-19 Impact, Size, Status and Forecast 2021-2027 sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Previously Rexgenero Ltd, a UK-based company developing cell therapies to treat serious diseases such as cancer and CLTI, the launch of Ixaka Ltd follows the integration of its nanoparticle gene therapy business in France and a shareholder restructuring.
The company reported that additional financing from existing shareholders, to the tune of over £40m (US$54.1m), will accelerate its proprietary multi-cell and targeted nanoparticle technologies.
Asked why there was a need for a company name change, Joe Dupere, Ixaka CEO, told BioPharma-Reporter:
Ixaka has offices in London, UK with R&D and manufacturing operations in Seville, Spain and Paris, France and additional manufacturing capability in Frankfurt, Germany.